{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "AVITA MEDICAL  DL-,0001", "longName": "AVITA Medical, Inc.", "messageBoardId": "finmb_4481298", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": -1.3888876, "regularMarketPrice": 14.2, "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.040540565, "fiftyTwoWeekLow": 4.3, "fiftyTwoWeekHigh": 14.8, "earningsTimestamp": 1683837000, "earningsTimestampStart": 1683837000, "earningsTimestampEnd": 1683837000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.95, "epsForward": -1.29, "epsCurrentYear": -1.44, "priceEpsCurrentYear": -9.861111, "sharesOutstanding": 25327800, "bookValue": 0.672, "fiftyDayAverage": 12.958, "fiftyDayAverageChange": 1.2419996, "fiftyDayAverageChangePercent": 0.09584809, "twoHundredDayAverage": 8.0752, "twoHundredDayAverageChange": 6.1247997, "twoHundredDayAverageChangePercent": 0.75847036, "marketCap": 368558144, "forwardPE": -11.007752, "priceToBook": 21.130953, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "AVITA Therapeutics, Inc.", "nameChangeDate": "2023-05-11", "averageAnalystRating": "1.6 - Buy", "tradeable": false, "cryptoTradeable": false, "priceHint": 2, "regularMarketChange": -0.19999981, "regularMarketTime": 1683892036, "regularMarketDayHigh": 14.2, "regularMarketDayRange": "14.2 - 14.2", "regularMarketDayLow": 14.2, "regularMarketVolume": 80, "regularMarketPreviousClose": 14.4, "bid": 13.6, "ask": 14.0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 14.2, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 9.9, "fiftyTwoWeekLowChangePercent": 2.3023255, "fiftyTwoWeekRange": "4.3 - 14.8", "fiftyTwoWeekHighChange": -0.6000004, "firstTradeDateMilliseconds": 1579158000000, "symbol": "51KA.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "28159 Avenue Stanford", "address2": "Suite 220", "city": "Valencia", "state": "CA", "zip": "91355", "country": "United States", "phone": "661 367 9170", "website": "https://www.avitamedical.com", "industry": "Medical Devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "AVITA Medical, Inc. operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a platform technology allows for the preparation and delivery of spray-on skin cells  to regenerate natural healthy epidermis, as well as to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Mr. James M. Corbett", "age": 64, "title": "CEO, Pres & Exec. Director", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 787103, "fmt": "787.1k", "longFmt": "787,103"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andrew  Quick", "age": 51, "title": "Chief Technology Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 615859, "fmt": "615.86k", "longFmt": "615,859"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 32182, "fmt": "32.18k", "longFmt": "32,182"}}, {"maxAge": 1, "name": "Ms. Donna  Shiroma", "age": 60, "title": "Gen. Counsel & Sec.", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 642719, "fmt": "642.72k", "longFmt": "642,719"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 82949, "fmt": "82.95k", "longFmt": "82,949"}}, {"maxAge": 1, "name": "Ms. Erin  Liberto", "age": 47, "title": "Chief Commercial Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 645097, "fmt": "645.1k", "longFmt": "645,097"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 103859, "fmt": "103.86k", "longFmt": "103,859"}}, {"maxAge": 1, "name": "Mr. Sean  Ekins", "age": 47, "title": "Interim CFO & Sr. VP of Fin.", "yearBorn": 1975, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David  Fencil", "title": "Sr. VP of Global Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Debbie  Garner", "title": "VP of Global Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Rob  Hall", "title": "VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Niraj  Doshi J.D., P.M.P., Ph.D.", "title": "Sr. VP of Product Devel. & Program Management", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ron  Lagerquist", "title": "Sr. VP of Quality Assurance & Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}